|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplemental Table 1. ARV Exposure** | | | | | |
|  | **Cross-sectional (n=70)** | | **Longitudinal (n=40)** | | |
|  | **Lifetime ARV Exposure, *N (%)*** | **Median lifetime years of exposure *(IQR)*** | **Current Exposure at Baseline, *N (%)*** | **Current Exposure at Last Visit *N (%)*** | **Median years of exposure during follow-up *(IQR)*** |
| **NRTI** |  | 16.0 (8-20) | 32 (80) | 31 (78) | 5.7 (1.9-8.4) |
| Abacavir | 27 (43)a | 0 (0-2.8) | 6 (15) | 4 (10) | 0 (0-0.7) |
| Didanosine | 43 (68)a | 0 (0-6.5) | 4 (10) | 2 (5) | 0 (0-0.4) |
| Emtricitabine | 54 (77) | 2.2 (0.2-6.0) | 13 (33) | 25 (63) | 2.7 (0-5.9) |
| Lamivudine | 52 (74) | 5.9 (0-9.5) | 13 (33) | 5 (13) | 0 (0-3.3) |
| Stavudine | 41 (59) | 5.3 (1.5-9.4) | 12 (30) | 2 (5) | 0 (0-0.4) |
| Tenofovir DF | 55 (79) | 3.1 (0.4-7.6) | 10 (25) | 23 (58) | 3.0 (0-5.6) |
| Zidovudine | 48 (76)a | 4.2 (0.2-9.4) | 10 (25) | 4 (10) | 0 (0-2.1) |
| **NNRTI** |  | 2.2 (0-7.0) | 15 (38) | 12 (30) | 0.9 (0-4.8) |
| Efavirenz | 27 (39) | 0 (0-2.2) | 8 (20) | 2 (5) | 0 (0-0) |
| Nevirapine | 16 (23) | 0 (0-0.003) | 4 (10) | 1 (3) | 0 (0-0) |
| Rilpivirine | 13 (19) | 0 (0-0) | 1 (2.5) | 6 (15) | 0 (0-0) |
| **PI** |  | 7.8 (1.2-14.0) | 22 (55) | 16 (40) | 2.7 (0-5.9) |
| Atazanavir | 23 (33) | 0 (0-0.6) | 2 (5) | 1 (3) | 0 (0-0) |
| Darunavir | 28 (40) | 0 (0-1.9) | 6 (15) | 13 (33) | 0 (0-1.7) |
| Indinavir | 14 (20) | 0 (0-0) | 3 (8) | 0 | 0 (0-0) |
| Lopinavir | 30 (43) | 0 (0-4.4) | 7 (18) | 1 (3) | 0 (0-0.6) |
| Nelfinavir | 27 (39) | 0 (0-2.4) | 4 (10) | 0 | 0 (0-0) |
| Ritonavir | 55 (79) | 4.1 (0.7-9.4) | 18 (45) | 16 (40) | 1.3 (0-5.3) |
| **INSTI** |  | 0.5 (0-2.7) | 8 (20) | 25 (63) | 0.6 (0-4.3) |
| Elvitegravir | 14 (20) | 0 (0-0) | 3 (8) | 7 (18) | 0 (0-0.1) |
| Dolutegravir | 15 (21) | 0 (0-0) | 0 | 6 (15) | 0 (0-0) |
| Raltegravir | 17 (24) | 0 (0-0.02) | 5 (13) | 7 (18) | 0 (0-1.2) |
| a Data available for 63 PLWH | | | | | |

Abbreviations: NRTI, nucleotide reverse transcriptase inhibitor; DF, disoproxil fumarate; NNRTI, non-nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor